LOS ANGELES--(BUSINESS WIRE)--Ritter Pharmaceuticals, Inc., a privately held pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, announces the appointment of Paul V. Maier to the Company’s Board of Directors. His addition increases Board membership to six directors. Mr. Maier will chair the Company’s audit committee.
“Paul brings us a wealth of operational and financial management expertise from his more than 25 years of experience as a senior executive in biotechnology and pharmaceutical companies,” said Ira Ritter, Chairman of the Board of Directors of Ritter Pharmaceuticals. “Paul’s counsel will prove valuable as we advance RP-G28 through the regulatory process and toward commercialization as the first treatment for lactose intolerance. We look forward to calling upon his extensive financial capabilities and corporate governance experience as he assumes the important position as audit committee chair. We are fortunate to have such a strong addition to our Board.”
Mr. Maier served for five years as the Chief Financial Officer of life sciences company Sequenom, Inc. (NASDAQ: SQNM), where he was instrumental in raising more than $360 million in equity and debt financing and commercializing the company’s molecular diagnostics segment. He previously served for 15 years as the Senior Vice President and Chief Financial Officer of Ligand Pharmaceuticals, Inc. (NASDAQ: LGND), where he helped build Ligand from a venture-stage company to a commercial, integrated biopharmaceutical organization. Prior to joining Ligand, Mr. Maier spent six years in various management and finance positions at ICN Pharmaceuticals (now Valeant Pharmaceuticals International, Inc.).
Mr. Maier currently serves on the Boards of Directors of International Stem Cell Corporation (OTCQB: ISCO), Apricus Biosciences (NASDAQ: APRI), MabVax Therapeutics (OTCQB: MBVX) and Biological Dynamics. He received an MBA from Harvard Business School and a BS from Pennsylvania State University.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Ritter is advancing human gut health research by exploring the metabolic capacity of gut microbiota and translating the functionality of these microbiome modulators into safe and effective applications. Ritter’s lead drug candidate, RP-G28, has the potential to become the first FDA-approved drug for lactose intolerance, a condition that affects more than one billion people worldwide.
This release may contain forward-looking statements, which express the current beliefs and expectations of Ritter Pharmaceuticals’ management. Such statements involve a number of known and unknown risks and uncertainties that could cause the company’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Any statements contained herein that do not describe historical facts, including but not limited to, statements regarding Mr. Maier’s expected contributions to Ritter’s Board of Directors are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.